The FDA issued a Complete Response Letter (CRL) for Incyte Corporation’s supplemental Biologics License Application for Zynyz (375mg) for the treatment of metastatic non-small cell lung cancer. The CRL cited regulatory compliance issues at a third-party fill-finish facility, Catalent Indiana, as the sole approvability concern and did not raise issues regarding the drug's efficacy or safety data.
